These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27379740)

  • 1. [Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers].
    Albrecht K; Huscher D; Eidner T; Kleinert S; Späthling-Mestekemper S; Bischoff S; Zink A
    Z Rheumatol; 2017 Feb; 76(1):50-57. PubMed ID: 27379740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account.
    Huscher D; Sengler C; Gromnica-Ihle E; Bischoff S; Eidner T; Ochs W; Richter J; Zink A
    Clin Exp Rheumatol; 2013; 31(2):256-62. PubMed ID: 23305590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.
    Emery P; Solem C; Majer I; Cappelleri JC; Tarallo M
    Rheumatol Int; 2015 Nov; 35(11):1837-49. PubMed ID: 26164150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today.
    Hagenow A; Seifert J; Zeissig A; Conrad K; Kleymann A; Aringer M
    Clin Exp Rheumatol; 2013; 31(2):213-8. PubMed ID: 23295192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
    Tan BE; Lim AL; Kan SL; Lim CH; Ng YF; Tng SLC; Hassin NS; Chandran L; Hamid NA; Lee YYL
    Rheumatol Int; 2017 Jun; 37(6):905-913. PubMed ID: 28389855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
    Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
    Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
    Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Databases of patients with early rheumatoid arthritis in the USA.
    Sokka T; Willoughby J; Yazici Y; Pincus T
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].
    Pattloch D; Richter A; Manger B; Dockhorn R; Meier L; Tony HP; Zink A; Strangfeld A
    Z Rheumatol; 2017 Apr; 76(3):210-218. PubMed ID: 27518855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
    Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.
    Listing J; Strangfeld A; Rau R; Kekow J; Gromnica-Ihle E; Klopsch T; Demary W; Burmester GR; Zink A
    Arthritis Res Ther; 2006; 8(3):R66. PubMed ID: 16600016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.
    Albrecht K; Callhoff J; Schneider M; Zink A
    Rheumatol Int; 2015 Aug; 35(8):1377-84. PubMed ID: 25663291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.